UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReuters UKAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, l…
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in study – Reuters
UPDATE 1-Amgen, Cytokinetics heart failure drug misses goal in studyReutersAMSTERDAM, Sept 3 (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leav…
Puducherry sets sights on organ donation and awareness – The Hindu
The HinduPuducherry sets sights on organ donation and awarenessThe HinduHave you thought about donating your eyes? If not, you may want to consider signing up to help the plight of the 300 odd people in Puducherry who are waiting for corneal transplant…
Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients – HealthCanal.com
|
Cardiac Resynchronization Therapy Fails for Certain Heart Failure Patients
HealthCanal.com COLUMBUS, Ohio – Researchers announced today that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and the international clinical trial ended early to prevent potential harm to patients. Cardiac Resynchronization Therapy offers no benefit beyond ICD therapy in …Medical Xpress ECHO-CRT: Resynchronization no help, may be harmful in narrow-QRS heart …TheHeart.Org Electromagnets guide heart device implantation, reduce radiation exposureWebWire (press release) MedPage Today –Forbes all 5 news articles » |
Amgen drug misses endpoint in acute heart failure trial – PMLiVE
Amgen drug misses endpoint in acute heart failure trialPMLiVEA drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial. During the ATOMIC-AHF trial involving 613 patients with…
More data backs Novartis' serelaxin in heart failure – PMLiVE
Business Recorder |
More data backs Novartis’ serelaxin in heart failure
PMLiVE Momentum continues to build behind Novartis’ heart failure candidate serelaxin, with new data from the European Society of Cardiology (ESC) meeting cementing its position as a blockbuster-in-waiting. A new analysis of data from the RELAX-AHF study has … Novartis heart failure drug effective across patient groupsReuters India Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple …ITNews Efficacy Of Novartis AG (ADR) (NYSE:NVS) For Heart FailuresPR Carbon (press release) |
Battling Kala azar: Indian scientists overcoming drug resistance – Business Standard
|
Battling Kala azar: Indian scientists overcoming drug resistance
Business Standard What was of interest to scientists was that the Leishmania parasite (that infects the liver and multiplies in the spleen) brings down the miRNA levels by “targeting an enzyme called dicer that is responsible for the production of these micro regulators … |
Rob Newman's rules of the road Three tips for touring – Chortle
|
Rob Newman’s rules of the road Three tips for touring
Chortle So, how do you prevent autopilot brain death? How do you snap out of it? How do you get back into the moment, all present and correct? I’ve asked around. Harry Hill once told me that if he ever feels this out-of-body experience creeping up on him … |
ADCB employees brighten lives through blood donation drive – AME Info (press release)
ADCB employees brighten lives through blood donation driveAME Info (press release)Abu Dhabi Commercial Bank (ADCB) recently held a blood donation drive at its Head Office in Abu Dhabi. A large number of employees from various divisions of the bank turn…
Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome – Medical Xpress
Hot Line IV: Late-breaking trials on heart failure and acute coronary syndromeMedical XpressThe blood pressure lowering drug aliskiren did not improve coronary artery disease when given to patients who had prehypertension, results of the Aliskiren Quan…